Share Price:

APNASPENAspen Pharmacare Hldgs2360671 (0.30%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Acquisition of rights to an anti-coagulant product from Novartis

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. Mono-Embolex is a heparin based anti-coagulant sold in the same… Continue reading Acquisition of rights to an anti-coagulant product from Novartis

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.